NFE2L2 and cancer: In prior research, Nrf2 was reported to be a good tumorigenesis initiator and chemotherapeutic essential antagonist, mediating drug resistance by regulating multiple pathways containing cancer-associated mutation, metabolic reprogramming, oncogene activation, and carcinogen exposure [58].